Advertisement

This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.

ACCEPT AND CLOSE

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

The key to knowledge is in your (nitrile-gloved) hands

Already an ACS Member?  

Basic

$0 Community Associate

ACS’s Basic Package keeps you connected with C&EN and ACS.

  • Access to 6 digital C&EN articles per month on cen.acs.org
  • Weekly delivery of the C&EN Essential newsletter
JOIN NOW
Standard

$80 Regular Members & Society Affiliates

ACS’s Standard Package lets you stay up to date with C&EN, stay active in ACS, and save.

Eligibility restrictions apply. Review ACS Membership Packages to see if you qualify.

JOIN NOW
Premium

$160 Regular Members & Society Affiliates
$55 Graduate Students
$25 Undergraduate Students

ACS’s Premium Package gives you full access to C&EN and everything the ACS Community has to offer.

  • Unlimited access to C&EN’s daily news coverage on cen.acs.org
  • Weekly delivery of the C&EN Magazine in print or digital format
  • Access to our Chemistry News by C&EN mobile app
  • Significant discounts on registration for most ACS-sponsored meetings
ACS offers discounts for some countries outside the United States. This discount is shown at checkout, if applicable.

JOIN NOW

Thank you!

Your account has been created successfully, and a confirmation email is on the way.

Your username is now your ACS ID.

ENJOY UNLIMITED ACCES TO C&EN

Mergers & Acquisitions

Venture capital firm buys genetically engineered–apple firm as part of a $53 million ag biotech deal

by Craig Bettenhausen
February 7, 2020 | A version of this story appeared in Volume 98, Issue 6
Advertisement

Most Popular in Business

 

On the left, a cut conventional apple, which has gone brown. On the right, a cut Arctic apple, which has not.
Credit: Okanagan Specialty Fruits
Okanagan silences the gene for polyphenol oxidase, resulting in apples that don't go brown as easily.

Okanagan Specialty Fruits, which makes apples genetically engineered to resist browning, is part of a $53 million sale of agricultural biotech assets. The sale is one element of a major restructuring at the biotech firm Precigen, which in January changed its name from Intrexon and changed CEOs to focus on health care. The buyer is the venture capital firm Third Security, which is run by former Intrexon CEO Randal J. Kirk, who is now chairman of Precigen.

Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society

You might also like...

Novozymes buys probiotics maker Synergia
Ingevity CEO Wilson resigns unexpectedly
Serving the chemical, life science, and laboratory worlds
Mark Douglas to be CEO of FMC

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.
GET MORE
GET MORE